

Statement of Standalone Unaudited Results for the Quarter & Nine Months ended 31.12.2023							
							(in Rs. Thousands)
Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from operations	13273.27	40680.96	53532.39	67955.65	90424.12	182511.20
II.	Other income	109.48	93.34	86.85	339.78	248.06	627.81
III.	Total Income (I+II)	13382.75	40774.30	53619.24	68295.43	90672.18	183139.00
IV.	Expenses						
	(a) Cost of materials consumed	5989.52	13824.44	46908.44	22641.85	64634.05	67179.40
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	254.32	13525.27	-41093.29	15240.35	-45683.80	-61.00
	(d) Employee benefits expense	8379.65	8489.54	11403.82	24119.11	22006.20	34616.07
	(e) Finance Costs	1561.61	1812.56	1062.89	4591.30	3147.93	3858.12
	(f) Depreciation and amortisation expense	4537.31	4322.62	4776.35	13047.75	14056.96	19320.89
	(g) Other expenses*	10188.16	12484.09	13124.62	31656.04	35281.12	55192.82
	Total expenses (IV)	30910.55	54458.52	36182.83	111296.40	93442.47	180106.31
V.	Profit/(Loss) from operations before exceptional items and tax (I-IV)	-17527.80	-13684.23	17436.41	-43000.97	-2770.29	3032.70
VI.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0
VII.	Profit/ (Loss) before tax (V-VI)	-17527.80	-13684.23	17436.41	-43000.97	-2770.29	3032.70
VIII.	Tax expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	2250.00
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	632.43
IX.	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	-17527.80	-13684.23	17436.41	-43000.97	-2770.29	1415.13
X.	Profit/(loss) from discontinued operations				0.00	0.00	
XI.	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0
XII.	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0
XIII.	Profit (Loss) for the period (IX+XII)	-17527.80	-13684.23	17436.41	-43000.97	-2770.29	1415.13
XIV.	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV.	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period	-17527.80	-13684.23	17436.41	-43000.97	-2770.29	1415.13
XVI.	Paid-up equity share capital (Face Value Rs 10)	37413.00	37413.00	37413.00	37413.00	37413.00	37413.00
XVII.	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):						
	(a) Basic	-4.68	-3.66	4.66	-11.49	-0.74	0.38
	(b) Diluted	0.00	0.00	0.00	0.00	0.00	0.00

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLG003504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004 - Gujarat (INDIA)

- Notes:**
1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14.02.2024
 2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and nine months ended 31st December, 2023
 3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
 4. Statement of Unaudited Financial Results of the company for the quarter and nine months ended 31st December, 2023, in the prescribed format under Schedule III of Companies Act, 2013
 5. The figures for the previous period have been regrouped wherever necessary.
 6. During the quarter under review, on 6th December 2023, a fire broke out at manufacturing facility of the company situated at Plot no. 20, Survey no. 52, Rajkot- Gondal national highway no.27, Hadamtala, Rajkot-360311, Gujarat resulted in loss / damage of Fixed assets, plant machineries, electrification of the Company. Process of assessing the actual damage due to fire is still under evaluation hence no effect of any loss due to fire is accounted in the financials of quarter and nine months ended 31.12.2023.
- * The Company has decided to gradually write off its all Preliminary and Pre-operative expenses which are forming the part of Balance Sheet accordingly Company has written off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

Place Hadamtala (Rajkot)
Date: 14.02.2024

FOR, PARMAX PHARMA LIMITED

U. Gosalia

Dr. Umang Gosalia
Managing Director



PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot – 360 004, Gujarat (INDIA)